Drug Trial Radar · NCT04910685
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
534
Planned (sponsor's estimate)
Start
Nov 30, 2021
Primary completion
Sep 30, 2032
Study completion Sep 30, 2032
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part K will enroll participants with ISM who have previously received an approved selective KIT inhibitor. The study also includes pharmacokinetic (PK) groups that will enroll participants with ISM.
Conditions
- Indolent Systemic Mastocytosis
- Smoldering Systemic Mastocytosis
Interventions
ElenestinibDrug
Elenestinib oral tablet
PlaceboDrug
Placebo oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 12 weeks
- Part 1: Mean change from baseline in ISM-Symptom in Assessment Form (ISM-SAF) Total Symptom Score (TSS)Time frame: Baseline, Week 13
- Part 2: Mean change from baseline in ISM-SAF TSSTime frame: Baseline, Week 49
- Part 3: Number of participants with Adverse Events (AEs)Time frame: Up to 5 years
- Part 3: Change from baseline in ISM-SAF TSSTime frame: Baseline up to 5 years
Locations
88 sites in 25 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Orso Health, Modena Allergy and Asthma Inc
La Jolla, California · Recruiting
David Geffen School of Medicine at UCLA
Los Angeles, California · Recruiting
Stanford Cancer Institute
Palo Alto, California · Recruiting
UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus
Aurora, Colorado · Recruiting
Winship Cancer Institute, Emory University
Atlanta, Georgia · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Michigan Medicine University of Michigan
Ann Arbor, Michigan · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
Duke Asthma, Allergy and Airway Center
Durham, North Carolina · Recruiting
University of Cincinnati Medical Center
Cincinnati, Ohio · Recruiting
The University of Texas, MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah · Recruiting
CHP Centro Hematologico Pavlovsky
Buenos Aires, Argentina · Recruiting
Consultorios Medicos Dr. Doreski - Fundacion Respirar
Buenos Aires, Argentina · Recruiting
The Canberra Hospital
Garran, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Kepler Universitatsklinikum, Med Campus III. Clinic of Internal Medicine 3 - Hematology and Oncology
Linz, Austria · Recruiting
Universitair Ziekenhuis Gent
Ghent, Belgium · Recruiting
CHU Tivoli
La Louvière, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Unitversitair Ziekenhuis Antwerpen
Edegem, Antwerpen, Belgium · Recruiting
Hospital das Clínicas da Faculdade de Medicina da USP - HCFMUSP
São Paulo, Brazil · Recruiting
Clinica Alemana de Santiago
Santiago, Chile · Recruiting
Fundación Valle del Lili
Cali, Colombia · Recruiting
Fakultní nemocnice Brno, Interní hematologická a onkologická klinika
Brno, Czechia · Recruiting
Fakultní nemocnice Královské Vinohrady, Hematologická klinika 3. LF UK v Praze a FNKV
Prague, Czechia · Recruiting
Odense University Hospital and University of Southern Denmark
Odense, Denmark · Recruiting
CHU Amiens-Picardie
Amiens, France · Recruiting
CHU de Caen
Caen, France · Recruiting
CHU Grenoble
Grenoble, France · Recruiting
CHU de Limoges
Limoges, France · Recruiting
CHU de Nantes
Nantes, France · Recruiting
Hôpital de la Pitié Salpétrière
Paris, France · Recruiting
Hôpital Necker - Départementd 'HématologieA dultes
Paris, France · Recruiting
CHU de Poitiers
Poitiers, France · Recruiting
CHU Toulouse - Hopital Larrey
Toulouse, France · Recruiting
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.